There’s been a disconnect for ages between pure research and the many millions it costs that companies are or aren’t willing to risk to try to bring those early results to market. And if there’s not a lot of money to be made to show for the risk their investors are looking at, they don’t back it. Dr. Denise Faustman of Harvard has a med that reverses Type 1 diabetes in mice and shows potential for other autoimmune conditions. It’s now in Phase II clinical trials only because patient advocacy groups helped fund it—it threatens a huge revenue stream of the insulin and pump manufacturers and they would not. (I’ve got a relative in Dr. Faustman’s study who has been very relieved and happy at how it’s working for her so far.)
BE THIS GUY over 9 years ago
I’m happy for the mice.
puddleglum1066 over 9 years ago
Has Darrin been reading “Skin Horse”?
amaryllis2 Premium Member over 9 years ago
There’s been a disconnect for ages between pure research and the many millions it costs that companies are or aren’t willing to risk to try to bring those early results to market. And if there’s not a lot of money to be made to show for the risk their investors are looking at, they don’t back it. Dr. Denise Faustman of Harvard has a med that reverses Type 1 diabetes in mice and shows potential for other autoimmune conditions. It’s now in Phase II clinical trials only because patient advocacy groups helped fund it—it threatens a huge revenue stream of the insulin and pump manufacturers and they would not. (I’ve got a relative in Dr. Faustman’s study who has been very relieved and happy at how it’s working for her so far.)